Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Jan 26, 2026
Reporting period
Not applicable
Filed with the SEC
Jan 27, 2026
CFOGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001193125-26-024824
Filed / recorded
Jan 27, 2026, 10:03 PM UTC
Added to OQRO
Oct 7, 2026, 6:56 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Larimar Therapeutics, Inc.
Issuer CIK
1374690
Ticker
LRMR
Reporting person
Michael Celano
Relationship
Officer
Officer title
Chief Financial Officer
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Jan 26, 2026
Transaction code
A
Shares / units
37,604
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
215,785
Ownership form
Direct
Amendment
No
Footnotes from the filing
Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.